title: A positive step forward, but more needed to maximize cost benefits of new-generation cancer therapies.
authors.forename: Ian E
authors.initials: IE
authors.lastname: Haines
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000191:economics; D002986:Clinical Trials as Topic / Q000592:standards* / Q000639:trends*; D016265:Conflict of Interest; D003362:Cost-Benefit Analysis / Q000639:trends*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine / Q000639:trends; D005544:Forecasting; D006801:Humans; D020714:Maximum Tolerated Dose; D008495:Medical Oncology / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents